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Abstract 
Background: The phase III MPACT trial demonstrated the superiority of gemcitabine (Gem) combined with Nab-paclitaxel (Nab-P) 
versus gemcitabine alone in previously untreated pa- tients with metastatic pancreatic ductal adenocarcinoma (PDAC). The purpose 
of this study was to evaluate the effect of Gem/Nab-P in routine clinical practice. Methods: From January 2015 to December 2018, 
patients with metastatic PDAC receiving first- line treatment with a combination of gemcitabine and Nab-paclitaxel were included in 
a multicen- tre retrospective observational study. Exploratory analyses of efficacy, and prognostic and predic-tive markers, were 
performed. Results: The cohort comprised 115 patients (median age 65 [range 50-84] years) with good perfor- mance status (ECOG 
PS 0-1). The median overall survival (OS) was 11 months (95% CI; 9-13) and the median progression-free survival (PFS) was 6 
months (95% CI 5-7). Partial response and stable disease were achieved in 44 and 30 patients, respectively, yielding an overall 
disease control rate (DCR) of 64.3%. Grade 3-4 hematological toxicity frequency was 22.61% for neutropenia, 5.22% for anemia, and 
3.48% for thrombocytopenia. Grade 3 asthenia was recorded in 2.61% of pa- tients. No grade 4 non-hematological events were 
reported. Dose reduction was necessary in 51.3% of the patients.  
Conclusion: Our results confirm the efficacy and safety of a first-line regimen comprising gemc- itabine and Nab-paclitaxel in 










Pancreatic adenocarcinoma represents the fourth leading cause of cancer-related deaths in Europe and the United States [1, 2]. It is 
an aggressive disease characterized by a very poor prognosis leading to a median overall survival (OS) of less than 18 months and 
a five-year OS rate below 8% [3]. To date, surgery is the only curative treatment avail- able, but this is limited to 20% of patients 
with respectable disease at the time of diagnosis and is often invalidated by re- currences. Bearing in mind the scarce initial 
symptomatolo- gy, most patients are diagnosed with locally advanced or me- tastatic disease, limiting the therapeutic approach to 
sys- temic chemotherapy [4] which has been associated with an improvement in disease-related symptoms and OS relative to the 
best supportive care [5]. Since 1997, based on pivotal trial results, single-agent gemcitabine has become the first-line standard of 
care in me- tastatic disease [5]. Subsequently, gemcitabine-based che- motherapy regimens have been compared with gemcitabine 
alone and, despite the higher response rates, have not im-  proved OS significantly due to increased toxicity [5-9]. Recently, two 
effective regimens have been introduced based on the results of large-scale clinical trials. The first, the FOLFIRINOX regimen, 
(i.e., 5-FU/leucovorin, irinote- can, and oxaliplatin), was introduced by the PRODIGE 4/ACCORD II trial which compared 
FOLFIRINOX with gemcitabine alone [10]. FOLFIRINOX treatment was shown to improve progression-free survival (PFS) and 
OS, respec- tively by 6.4 and 11 months, compared with 3.3 and 6.8 months obtained with gemcitabine. Due to the higher toxici- 
ty rate compared to gemcitabine, FOLFIRINOX is consid- ered the preferred regimen for patients with metastatic pan- creatic 
cancer and good performance status (PS) as well as normal organ functions [10]. Moreover, a second regimen with gemcitabine 
and Nab-- paclitaxel (Gem/Nab-P) has been introduced through a larg- er randomized phase 3 trial (MPACT), demonstrating the 
su- periority of the combination regimen over gemcitabine alone in previously untreated patients with metastatic pancreatic 
adenocarcinoma [11]. The median PFS was 5.5 months and OS was 8.5 months in the Gem/Nab-P group, compared to 3.7 and 
6.7 months in the gemcitabine group, respectively. Thus, the combination of gemcitabine and Nab-Paclitaxel has been established 
as another standard first-line treatment for metastatic pancreatic cancer [11]. The most common seri- ous adverse events reported 
with the combination therapy were neutropenia, fatigue and neuropathy. Currently, FOLFIRINOX and Gem/Nab-P are recom- 
mended as the first-line regimens for metastatic pancreatic cancer; FOLFIRINOX is the option of choice in younger pa- tients with 
good PS, but whether the combination is superior to Gem/Nab-P in advanced pancreatic cancer has not yet  been clarified [12, 13]. 
The strict enrolment criteria and sev- eral intrinsic limitations related to randomized clinical trial protocols mean that the samples 
enrolled in trials to date have not been representative of the population in clinical practice. Phase IV studies on Gem/Nab-P 
treatment have not yet been performed. The aim of this retrospective study is to evaluate the effectiveness and safety of 
gemcitabine and Nab-paclitaxel treatment for metastatic pancreatic cancer in a real-world setting. 
 
2. METHODS 
2.1. Study Population 
Patients with metastatic pancreatic ductal adenocarcino- ma (PDAC), receiving first-line treatment with a combina- tion of 
gemcitabine and Nab-paclitaxel from January 2015 to December 2018, were considered eligible for our retro- spective analysis. 
Inclusion criteria were the following: age ≥18 years; his- topathologically confirmed PDAC; Eastern Cooperative On- cology 
Group performance status (ECOG-PS) 0-1, adequate hematological function (neutrophil count ≥1500/mm
3
, platelet count 
≥100,000/mm
3
, and hemoglobin ≥ 9 g/dl); no hepatic or renal impairments. Patients with locally advanced cancer, patients who 
re- ceived previous chemotherapy treatment or histology other than PDAC were excluded. Written informed consent was 
obtained from each patient before starting treatment. This study was approved by the Comitato Etico Regionale for clinical 
experimentation of Toscana region (Italy) area vasta centro section, number:14565_oss treatment in accordance with the 
Declaration of Helsinki. 
2.2. Treatment Schedule 
The initial dose of Gem/Nab-P was chosen according to a previous phase III study (MPACT): 30-40 minutes of intra- venous 
infusion of Nab-paclitaxel 125 mg/m
2
, followed by 30 minutes of gemcitabine 1000 mg/m
2 
diluted with 250 ml of saline 
solution administered intravenously on days 1, 8 and 15 every 4 weeks [11]. Dexamethasone 8mg and On- dansetron 8mg 
Slow bolus/15 min infusion and ranitidine 50mg Intravenous Slow bolus were used as premedication to start chemotherapy. 
Recombinant human granulocyte colony-stimulating factor and erythropoietin were adminis- tered as needed. Treatment was 
modified depending on physician/patient choice, and treatment was continued until disease progression or unacceptable 
toxicity. 
2.3. Assessment 
Tumor response evaluation was performed every 3 months by spiral computed tomography (CT). Disease pro- gression was 
assessed as either radiological or clinical pro- gression. The best response during Gem/Nab-P treatment was radiologically 
evaluated according to the Response Eval- uation Criteria in Solid Tumour (RECIST) version 1.1 [14]. Blood tests were 
performed at baseline and every thera- py cycle, while measurement of the carbohydrate antigen (CA)19-9 serum level was 
performed at baseline and every 12 weeks. Efficacy has been evaluated as OS and PFS. Adverse events during Gem/Nab-P 
treatment were moni- tored by investigators and reported in clinical charts. Treat- ment-related Adverse Events (AEs) were 
assessed using the Common Terminology Criteria of Adverse Events (CTCAE) version 4.0 [15]. Variables assessed for 
prognostic correlations included age ≥70 years, sex, ECOG-PS, primary tumor site, baseline CA19-9 level ≥ 659 × ULN, 
number of metastatic sites, basal levels of LDH, Gamma-GT, and ALP (calculated as the absolute neutrophil count divided by 
the absolute lym- phocyte count measured in × 10
3
/ml), previous surgery, radia- tion therapy, and biliary stent implantation. In 




P and to 800 or 600 mg/m
2 
for gemcitabine). A missing dose within four days of the scheduled administra- tion was considered 
a dose delay. 
2.4. Clinical Outcomes 
The primary endpoints were OS and a PFS. The se- condary endpoints were disease control rate (DCR) as well as the rate and 
severity of treatment-related AEs. Overall sur- vival was defined as the time from the diagnosis of ad-vanced pancreatic cancer 
to death from any cause or the date of the last follow-up visit. Progression-free survival was defined as the time from the initial 
assessment at the cancer center to the date of the disease progression, as reported by the clinician. Disease control rate was 
defined as the propor- tion of patients with the best overall response determined as complete response (CR), partial response 
(PR) or stable dis- ease (SD). No CR was recorded in our sample. 
Table 1. Patient characteristics. 
 





































































2.5. Statistical Analysis 
All patients were included in the statistical analysis. De- scriptive statistics were carried out on the clinical parame- ters of the 
PC. Time-dependent outcomes were estimated us- ing the Kaplan-Meier method and compared, at univariate analysis, using the 
log-rank test. Parameters with a statistical- ly significant log-rank test were considered independent vari- ables and included in the 
multivariate Cox proportional hazard regression linear model to compare hazard ratio (HR) and 95% confidence interval (95% 
CI). A two-sided p-value < 0.05 was considered statistically significant. STATA v.2012 was used for statistical analysis. 
3. RESULTS 
3.1. Study Population 
Overall, from January 2015 to December 2018, 143 pa- tients with metastatic pancreatic cancer treated with Gem/N- ab-P 
have been identified. Among them, 29 patients were ex- cluded based on the exclusion criteria. Thus, a sample of 115 patients 
has been used for efficacy and safety analysis. Patients’ characteristics are described in Table 1. The me- dian age was 65 years 
(range 50-84) with a male: female ra- tio 61:54. ECOG-PS was 0 in 46.1% of patients and one in 53.9%. The most frequent 
metastatic sites were liver (56%), lung (24.3%), and peritoneum (13.9%); 69% of patients had 1-2 metastatic sites, and 40% 
 
had three or more. Radiation therapy has been performed in 8.7% of the cohort, whereas 24.3% and 33% have been treated 
with surgery and biliary stent, respectively. None of the patients has received previ- ous chemotherapy. Median baseline CA 
19.9 was 659 U/ml (range 0.8-182,922 U/ml). Forty-eight (41.7%) patients re- ported cancer-related pain or other disease-
related symp- toms before treatment. Our population study presented with comorbidities: the most frequent was cardiovascular 
48 (41.7%) (Table 1S), and 37 (32.2%) patients presented with 
>1 comorbidity. 
3.2. Treatment 
During the study, patients received a median of five cy- cles (range 1–17) of treatment with a starting dose of Nab-P 125 
mg/m
2 
plus Gem 1,000 mg/m
2
. Dose reduction was ne- cessary for 59 (51.3%) patients without significant differ- ence between 
gemcitabine and Nab-paclitaxel; 63 (54.8%) required only one dose reduction, whereas 32 (27.8%) had two dose reductions. 
Dose delays and treatment interruption occurred in 43 (37.4%) and 44 (38.4%) patients, respective- ly. Neutropenia, peripheral 
neuropathy, and asthenia were the main cause of dose reductions, delays or stopping treat- ment. 
3.3. Efficacy 
Overall, the median follow-up period was 10 (range 1-54) months. The median OS was 11 months (95% CI; 9-13) and the 
median PFS was 6 months (95% CI 5–7). Par- tial response and stable disease were recorded in 44 and 30 patients, 
respectively, yielding an overall DCR of 64.3% (Table 2). For 9 (7.8%) patients, the response was not evalu- able. Regarding 
survival, univariate analysis showed that age, ECOG-PS 1, Ca 19.9 U/ml ≥ 659 U/ml and number of me- tastatic sites ≥ 3 were 
negatively correlated with OS. In fact, OS was statistically lower according to age (9 vs. 13  months, p = 0.002, Fig. 1); ECOG-
PS (10 vs. 13 months, p =0.04, Fig. 1); Ca 19.9 (10 vs. 14 months, p = 0.01, Fig. 1) number of metastatic sites (8 vs. 13 
months, p = <0.001, Fig.1). Conversely, previous surgery, cycles of Gem/Nab-P >4 and more than one line of treatment for 
metastatic disease were correlated with a better OS that was statistically higher according to previous surgery (13 vs. 10 
months, p = 0.03, Fig. 2); cycles of Gem/Nab-P (14 vs. 6 months, p = <0.001,Fig. 2); and lines of treatment (13 vs. 9 months, 
p = 0.01, Fig. 2). Other variables examined did not show statistically significant effects (Table 3). Multivariate analysis has 
con- firmed metastatic sites ≥ 3 (HR 1.68; 95% CI 1.15–3.15; p = 0.04) and CA 19.9 levels ≥ 659 U/ml (HR 1.84; 95% CI 
1.19–2.82; p = 0.006) were correlated with a worse OS (Table 4). On the other hand, previous surgery (HR 0.31; 95% CI 0.17–
0.55; p = 0.001), cycles of Gem/Nab-P > 4 (HR 0.21; 95% CI 0.13–0.35; p = 0.001), and lines of treat- ment for metastatic 
disease >1 (HR 0.47; 95% CI 0.30–0.73; p = 0.001), were correlated with a better overall survival (Table 4). 
Table 2. The best response, PFS, and OS according to neutrope- nia grade. 
 
 All Patients (N=115) 
PR 44 (38.3%) 
SD 30 (26.1%) 
DCR 
(PR + SD) 
74 (64.3%) 
PD 32 (27.8%) 
NE 9 (7.8%) 
PFS M-months (95% IC) 6 (5-7) 




GCF-Prophylaxis 25 (21.9)%) 
Number (N), partial response (PR), stable disease (SD), disease control rate (DCR), progression disease (PD), not evaluable (NE); Median (median); progression free survi- val (PFS); 
overall survival (OS). 
 
Regarding progression-free survival, univariate analysis showed that the number of metastatic sites ≥ 3, the baseline level of CA 
19.9 U/ml ≥ 659 U/ml, and pain were negatively correlated with PSF (Table 3). Multivariate analysis has con- firmed the number 
of metastatic sites ≥ 3 (HR 2.73; 95% CI 1.41–5.27; p = 0.003) and CA 19.9 levels ≥ 659 U/ml (HR 1.67; 95% CI 1.08–2.57; 
p = 0.02) as an independent, nega- tive and prognostic indicators for PFS, respectively (Table 4). 
3.4. Safety 
Hematological and non-hematological adverse event fre- quencies are shown in Table 5. Overall, the treatment was well-
tolerated, and most non-hematological toxicities were reported as grade 1 or 2. In our cohort, the frequency of grade 3 bone 
marrow toxicity was 15.56% for neutropenia, 2.61% for anemia, and 2.61% for thrombocytopenia. Grade 4 hematological 
toxicity comprised neutropenia in 8 patients (6.96%), anemia in 3 (2.61%), and thrombocytopenia in 1 (0.87%). The only grade 3 
non-hematological toxicity was asthenia recorded in 3 patients (2.61%). No grade 4 non-he- matological events were reported. 
 
4. DISCUSSION 
Our Italian retrospective study seems to confirm the treat- ment benefit of Gem/Nab-P treatment in patients with me- tastatic 
pancreatic cancer in a real-world setting, according to the result of the randomized phase III MPACT trial [11]. Several factors, 
including small sample size and differ- ences in inclusion/exclusion criteria, meant that a direct com- parison between the 
pivotal MPACT trial and this real-- world experience was not fully possible. However, despite the limitations, we were able to 
confirm that the combina- tion regimen with Gem/Nab-P was effective and safe in our population compared with the 
randomized controlled trial sample. Specifically, we observed 11 months median OS and 6 months median PFS with a DCR of 
64.3%. When comparing our results with those of the pivotal trial, there are some differences in patients’ characteristics that 
we need to consider. In the MPACT trial, patients were younger, with approximatively 60% of the participants aged below 65, 
with a Karnofsky Performance Status (KPS) of 100-90% [16]. On the other hand, 33% of patients in our sample were older 
than 70 years and 46.1% have reported an ECOG-PS 0. Additionally, we treated 32% of patients with >1 concomitant 
comorbidities (Table 1s). All these data sup- port the use of Gem/Nab-P in a “real-life” population of elderly patients with 
varying  comorbidities. Recent retrospective studies in patients with both me- tastatic and locally advanced disease have 
reported a differ- ence in efficacy data between metastatic and locally ad- vanced subgroups. For example, Wang et al. 
achieved an  OS of 10.5 months in the total cohort and similar survival of 10 months in the metastatic subgroup [21]. Recently, 
Bloms- trand et al. observed a trend towards better prognosis in the locally advanced group of 22 patients. PFS and OS were 
6.8 and 17.1 months, respectively in the locally advanced group, compared to 4.5 and 9.4 months in the metastatic group of 53 
patients, although the differences reported were not statis- tically significant [22]. In another multicentre retrospective study on 
elderly patients, PFS and OS were 12.1 and 21.8 months in 42 patients with locally advanced cancer and 5.9 and 13.3 months 
in 59 patients with metastasis, respectively [23]. In our study, according to the MPCT trial, we have en- rolled only chemo-
naïve patients with upfront metastatic dis- ease. Unfortunately, subgroup analysis on metastatic burden has shown a worse 
prognosis for patients with three or more metastases, a difference statistically significant in relation to OS (HR 1.68; 95% CI 
1.15–3.15; p = 0.04) and PFS (HR 2,73;  95%  CI  1.41–5,27;  p = 0.003),  suggesting  the main role of tumor burden as a 
prognostic factor in metastatic pan- creatic cancer. Several investigators have reported their experience with Gem/Nab-P in 
clinical practice in patients with locally ad- vanced and metastatic pancreatic cancer, based on retrospec- tive studies. De Vita 
and colleagues have reported a median PFS and OS of 6.7 and 10 months, respectively, enrolling a cohort of 41 patients [17]. 




Fig. (1). Overall survival of Gem/Nab-P according to different prognostic factors: age, ECOG, CA 19.9, and metastatic sites. (A higher reso- 





Fig. (2). Overall Survival of Gem/Nab-P according to different prognostic factors: surgery, cycles of therapy, and lines of treatment. (A high- 
er resolution / colour version of this figure is available in the electronic copy of the article.) 
 
 
Table 3. Univariate analysis for PFS and OS. 
 
 HR IC 95% P 
Progression free Survival 
Age ≥70 1.44 0.93-2.24 0.1 
ECOG PS (1 vs 0) 1.17 0.78-1.77 0.4 
Sex (male vs female) 1.08 0.71-1.64 0.7 
N. of metastatic sites ≥3 3.85 2.06-7.20 0.001 
Carbohydrate antigen 19-9 
≥ 659U/ml 
1.86 1.23-2.83 0.003 
Previous Radiation Therapy 0.63 0.29-1.37 0.2 
Previous Surgery 0.76 0.47-1.26 0.2 
Previous Biliary stent 0.75 0.48-1.17 0.2 
Pain present 1.51 1-2.31 0.05 
LDH 
≥ 163.5 U/ml 
0.80 0.51-1.25 0.3 
Gamma-gt 
≥ 72 U/ml 
1.02 0.68-153 0.9 
ALP 
≥ 112 U/ml 
0.98 0.66-1.50 0.9 
Overall Survival 
Age ≥70 1.88 1.23-2.89 0.004 
ECOG PS (1 vs 0) 1.52 1-2.31 0.05 
Sex (male vs female) 1.20 0.79-1.83 0.4 
N. of metastatic sites ≥3 3.91 2-7.63 <0.001 
Carbohydrate antigen 19-9 
≥ 659U/ml 
1.71 1.22-2.60 0.01 
Previous Radiation Therapy 0.47 0.19-1.16 0.1 
Previous Surgery 0.58 0.35-0.99 0.04 
Previous Biliary stent 0.84 0.54-1,32 0.4 
Pain present 1.50 0.98-2.29 0.06 
LDH 
≥ 163.5 U/ml 
0.77 0.47-1.24 0.3 
Gamma-gt 
≥ 72 U/ml 
1.08 0.71-1.65 0.7 
ALP 
≥ 112 U/ml 
0.96 0.63-1.44 0.8 
Cycles of NabGem >4 0.28 0.18-0.44 0.001 
Lines of treatment for metastatic disease>1 0.60 0.39-0.91 0.01 
 
5.5 and OS of 12.1 months [18]. Montes et al. recorded in a sample of 39 patients slightly longer PFS and OS (9 and 15 
months, respectively), different from the study of Nea Papne- ja et al. that reported, in a cohort of 33 patients, a shorter PFS 
and OS of 4 and 9 months, respectively [19, 20]. Com- pared with all these studies, we evaluated a greater number of patients 
from different institutions, confirming the effica- cy of Gem/Nab-P as a first-line treatment for metastatic pan- creatic cancer. 
No standard second-line treatment following the failure of first-line chemotherapy has been available to date, and questions 
related to treatment choice and sequence are ongo- ing. However, second-line chemotherapy produced a survi- val benefit 
when compared with best supportive care and was found to be more effective in patients with early progression within 3 
months after first-line treatment [24-26]. In  our study, an increased OS was recorded in patients with two or more 
treatment lines for metastatic disease (HR 0.47; 95% CI 0.30–0.73; p = 0.001), supporting the role of a se- cond or further 
line of treatment as prognostic of survival  for metastatic pancreatic cancer. To note, the safety profile in our study was 
better com- pared to the pivotal trial and other previous studies [11, 18, 19, 28]. Adverse non-hematological events were 
generally of grade 2 or 1; no grade 3 or 4 peripheral neurotoxicity was observed in our cohort. Grade 3 asthenia was 
reported in 2.61% of patients, in contrast with data of the MPACT study (17%). Grade 3 or 4 hematological toxicity was 
observed in a lower percentage than the pivotal trial, consistent with the data reported in the previous studies in clinical 
practice [17, 18, 22, 23]. 
 
 
Table 4. Multivariate analysis for PFS and OS. 
 
 HR IC 95% P 
Progression-free Survival 
N. of metastatic sites ≥3 2.73 1.41-5.27 0.003 
Carbohydrate antigen 19-9 
≥ 659U/ml 
1.67 1.08-2.57 0.02 
Pain present 1.30 0.84-2.01 0.23 
Overall Survival 
Age ≥70 1.18 0.74-1.87 0.5 
ECOG PS (1 vs 0) 1.05 0.69-1.67 0.8 
N. of metastatic sites ≥3 1.68 1.15-3.15 0.04 
Carbohydrate antigen 19-9 
≥ 659U/ml 
1.84 1.19-2.82 0.006 
Previous Surgery 0.31 0.17-0.55 0.001 
Cycles of NabGem >4 0.21 0.13-0.35 0.001 
Lines of treatment for metastatic disease >1 0.47 0.30-0.73 0.001 
 
Table 5. Summary of most ≥3 adverse events for NabGem. 
 
 Grade 3 Grade 4 






Neutropenia 18 (15.65%) 
Anemia 3 (2.61%) 
Thrombocytopenia 3 (2.61%) 
Non-Hematological 15* (13.04%) 
Neuropathy 14* (12.17%) 
Diarrhea 3 (2.61%) 
Asthenia  
*Grade 1; ** Grade 2 
 
Overall, the regimen was well tolerated, in line with pre- vious studies, although some patients required dose reduc- tion or 
treatment discontinuation. Based on a retrospective analysis of the MPACT trial, the dose reduction and/or de- lay of 
chemotherapeutic drugs to manage toxicities can be carried out with no reductions in the efficacy of the estab- lished starting 
dose [29]. Among other prognostic factors related to PFS and OS, we found that baseline CA 19.9 value ≥ 659 U/ml was linked 
to a worse OS. In line with these data, several studies retrospectively investigated the prognostic role of basal CA19.9  during  
first-line  chemotherapy  [30].  The  role  of CA 19.9 in pancreatic cancer is well established, National Com- prehensive Cancer 
Network (NCCN] guidelines for pancreat- ic cancer recommends CA19.9 as the only biomarker of dis- ease; in fact, CA 19.9 is 
strongly correlated with tumor bur- den [30]. Nonetheless, the optimal level of CA 19.9 as a prognostic factor remains uncertain, 
because while we found a value of 659 U/ml, other studies found both higher than lower values. Future prospective studies are 
awaited to define the best basal value of CA 19.9 as a predictor of survi- val during first-line Gem/Nab-P. In addition, we also 
found >4 cycles of therapy to be an independent positive prognostic factor associated with OS. In this context, Lo Re et al. [18] 
confirmed a longer OS for patients treated with ≥ 4 cycles of Gem/Nab-P. Although it might be intuitive that more cycles of 
therapy would corre- late with a longer OS, it is worth noting that 6 cycles of Gem/Nab-P therapy are typical in order to try to 
avoid exces- sive toxicity. The optimal duration of Gem/Nab-P therapy therefore requires further investigation. Furthermore, >1 
lines of treatment for metastatic disease correlated with a bet- ter OS (we will describe the role of second-line therapy after 
Gem/Nab-P therapy in a separate paper). Finally, no statisti- cally significant correlation between OS and ECOG-PS was 
highlighted, contrasting with Lo Re et al. [18] who reported a correlation between PS <2 and a higher number of therapy cycles, 
allowing an increase in OS, supporting no efficacy of Gem/Nab-P for patients with PS=2. Our study has some limitations mainly 
owing to its retro- spective nature. The largest sample compared to that of pre- vious studies, and the enrolment of only 
metastatic patients, represent strengths aimed at increasing knowledge about the efficacy and safety of Gem/Nab-P in patients 
with stage IV disease. 
CONCLUSION 
Progress has recently been made in the first-line of che- motherapy in locally advanced and metastasized pancreatic cancer. 
Studies of further lines of therapy are ongoing. In  the absence of randomized control trials, the choice of the first-line 
chemotherapy between Gem/Nab-P and FOLFIRI- 
 
 
NOX in patients with metastatic pancreatic cancer is mainly based on careful patient selection, their performance status, 
comorbidity, and medical preference. Our study confirms the activity, efficacy, and safety of gemcitabine plus Nab-P as a first-
line regimen, in a large group of patients with ex- clusive metastatic pancreatic cancer, in a real-world setting. Despite clinical 
efficacy and the overall good tolerance of therapy, the identification of serum or tissue markers could allow a personalized and 
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